Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia |
| |
Authors: | Anargyrou Konstantinos Vaiopoulos George Terpos Evangelos Tsironi Maria Konstantopoulos Konstantinos Samarkos Michael Meletis John |
| |
Affiliation: | First Department of Internal Medicine, University of Athens School of Medicine, Laiko General Hospital, Greece. |
| |
Abstract: | We present the case of a 71 year-old man with secondary acute myeloblastic leukemia, who was successfully treated with low dose melphalan plus Epo plus G-CSF. We treated the patient with 2 mg of melphalan once a day orally, G-CSF 5 mg/kg 3 times a week and Epo 10.000 ui subcutaneously 3 times a week until the maximum response was obtained. Complete remission was achieved after 16 weeks of continuous treatment. Treatment-related toxicity was not significant. We recommend the use of low dose melphalan in elderly patients with high risk MDS as a treatment option. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|